EFFICACY & SFTY OF SHRT CORSE ANTIRETROVIRAL THRPY FOR ACUTE OR RECNT HIV-1 INF

功效

• 批准号: 7604491
• 负责人: MICHELLE A. BARRON
• 金额: $ 1.24万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604491
• 关键词: Acute; Adverse effects; Anti-HIV Agents; Anti-Retroviral Agents; Blood; Chronic; Computer Retrieval of Information on Scientific Projects Database; Drug usage; Funding; Grant; HIV; HIV Infections; Immune system; Institution; Learning; Lopinavir; Lopinavir/Ritonavir; Medicine; Pharmaceutical Preparations; Research; Research Personnel; Resources; Ritonavir; Source; Tenofovir; Time; United States Food and Drug Administration; United States National Institutes of Health; Viral Load result; Virus; improved; truvada; Acute; Adverse effects; Anti-HIV Agents; Anti-Retroviral Agents; Blood; Chronic; Computer Retrieval of Information on Scientific Projects Database; Drug usage; Funding; Grant; HIV; HIV Infections; Immune system; Institution; Learning; Lopinavir; Lopinavir/Ritonavir; Medicine; Pharmaceutical Preparations; Research; Research Personnel; Resources; Ritonavir; Source; Tenofovir; Time; United States Food and Drug Administration; United States National Institutes of Health; Viral Load result; Virus; improved; truvada

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is being done to learn if treating people during early HIV infection is beneficial. In other words, this study will evaluate how safe and effective a combination of anti-HIV drugs (emcitrabine plus tenofovir (Truvada) and lopinavir plus ritonavir (Kaletra) is for people with recently acquired HIV infection. It is known that combination anti-HIV drugs decreases the amount of virus in the blood (viral load) and improve the immune system. However, these drugs also have short-term and long-term side effects that are also considered when people decide whether or not to begin anti-HIV medicine. The opinions of HIV treatment experts regarding when to start anti-HIV medicine do change as we learn more about the anti-HIV drugs and their good and bad effects over time. The three drugs used in this study have been approved of by the U.S. Food and Drug Administration for the treatment of people with chronic HIV infection.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 正在进行这项研究以了解是否在早期艾滋病毒感染期间治疗患者是有益的。换句话说，这项研究将评估抗HIV药物（Emcitrabine Plus Tenofovir（Truvada）和Lopinavair Plus Ritonavir（Kaletra）的安全和有效的结合，对于最近获得的HIV感染的人来说是针对最近获得的抗HIV感染的人。众所周知，抗HIV药物的结合也可以减少流体量的替代药物（病毒疗法），并改善了这些术语的量子（这些术语）。当人们决定是否开始抗HIV治疗专家何时开始抗HIV药物的意见时，当我们对抗HIV药物的更多信息及其在本研究中使用的三种药物批准了抗HIV的副作用。